Novo's Wegovy cuts BMI by 17.4% in obese children aged 6 to 11 in late-stage trial

A semaglutide injection pen lying in front of its box.
Photo by Haberdoedas on Unsplash

Novo Nordisk (NVO) released full results on Monday from a late-stage trial in which its Wegovy injection lowered body mass index (BMI) by 17.4% in children aged 6 to 11 with obesity, CNBC reports.

BMI rose 2.2% over the same 68 weeks in children given a placebo, an estimated gap of 19.7 percentage points among children who stayed on treatment. Counting every child in the trial, including those who stopped taking the drug, the gap was 16.2 points. All 167 children also followed a reduced-calorie diet and increased their physical activity.

Many of the children had serious obesity going in. About 85% had moderate or severe obesity, and nearly half already had a related condition such as high blood pressure, high cholesterol or sleep apnea.

By the end of the study, more than 40% of the children who stayed on Wegovy no longer met the definition of obesity, a result Novo first shared in September.

Novo said the drug's safety and tolerability in children were in line with its adult trials, and that it found no safety concerns related to growth or puberty.

"This is a very significant disease burden in this very young patient population," Andrea Traina, Novo's medical director lead of obesity, told CNBC.

Wegovy is already approved for obesity in patients 12 and older, but no drug is approved to treat common obesity in younger children. The World Obesity Federation estimates that about 177M children and teens aged 5 to 19 had obesity in 2025.

Traina cautioned that the study cannot show whether treating obesity this early changes how the disease develops into adulthood, calling it "still an evidence gap." CNBC's report did not say when Novo plans to seek approval for the younger age group.

Wegovy injections brought in DKK 20.4B of third-quarter sales, flat from a year earlier, while the newer Wegovy pill added DKK 5.4B.

Novo's US-listed shares were up 0.7% as of 10:33 a.m. ET.

Sources & Further Reading

  1. "Novo says Wegovy injection lowers BMI and obesity rates in children in trial." CNBC. November 16, 2026.
  2. "Novo Nordisk Q3 2026 Financial Report." Novo Nordisk. November 4, 2026.

This article was drafted with the help of AI. Kyle Vallans fact-checked, edited and published the article and is responsible for its accuracy and quality. How we use AI